292 related articles for article (PubMed ID: 15363032)
1. Malignancies in organ transplant recipients.
Hoshida Y; Aozasa K
Pathol Int; 2004 Sep; 54(9):649-58. PubMed ID: 15363032
[TBL] [Abstract][Full Text] [Related]
2. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience.
Ju MK; Joo DJ; Kim SJ; Huh KH; Kim MS; Jeon KO; Kim HJ; Kim SI; Kim YS
Transpl Int; 2009 Jun; 22(6):644-53. PubMed ID: 19220824
[TBL] [Abstract][Full Text] [Related]
3. Cancer incidence after immunosuppressive treatment following kidney transplantation.
Andrés A
Crit Rev Oncol Hematol; 2005 Oct; 56(1):71-85. PubMed ID: 15978827
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512
[TBL] [Abstract][Full Text] [Related]
5. [Skin cancer in renal transplant recipients].
Mangino M; Schena FP
G Ital Nefrol; 2010; 27 Suppl 50():S75-80. PubMed ID: 20922700
[TBL] [Abstract][Full Text] [Related]
6. A population-based study of skin cancer incidence and prevalence in renal transplant recipients.
Moloney FJ; Comber H; O'Lorcain P; O'Kelly P; Conlon PJ; Murphy GM
Br J Dermatol; 2006 Mar; 154(3):498-504. PubMed ID: 16445782
[TBL] [Abstract][Full Text] [Related]
7. Melanomas in renal transplant recipients.
Le Mire L; Hollowood K; Gray D; Bordea C; Wojnarowska F
Br J Dermatol; 2006 Mar; 154(3):472-7. PubMed ID: 16445778
[TBL] [Abstract][Full Text] [Related]
8. Malignancy in renal recipients.
Samhan M; Al-Mousawi M; Donia F; Fathi T; Nasim J; Nampoory MR
Transplant Proc; 2005 Sep; 37(7):3068-70. PubMed ID: 16213307
[TBL] [Abstract][Full Text] [Related]
9. Urological malignancy after renal transplantation.
Besarani D; Cranston D
BJU Int; 2007 Sep; 100(3):502-5. PubMed ID: 17669141
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of HTLV-I-positive renal transplant recipients.
Nakamura N; Tamaru S; Ohshima K; Tanaka M; Arakaki Y; Miyauchi T
Transplant Proc; 2005 May; 37(4):1779-82. PubMed ID: 15919464
[TBL] [Abstract][Full Text] [Related]
11. Malignancies after renal transplantation in southern Taiwan: experience in one centre.
Feng WW; Wang TN; Chen HC; Ho JC; Ko YC
BJU Int; 2007 Apr; 99(4):825-9. PubMed ID: 17155978
[TBL] [Abstract][Full Text] [Related]
12. De novo malignancies after liver transplantation: a major cause of late death.
Fung JJ; Jain A; Kwak EJ; Kusne S; Dvorchik I; Eghtesad B
Liver Transpl; 2001 Nov; 7(11 Suppl 1):S109-18. PubMed ID: 11689783
[TBL] [Abstract][Full Text] [Related]
13. De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation.
Aseni P; Vertemati M; De Carlis L; Sansalone CV; Bonacina E; Minola E; Oreste P; Vizzotto L; Rondinara G
Pathol Int; 2006 Nov; 56(11):712-5. PubMed ID: 17040297
[TBL] [Abstract][Full Text] [Related]
14. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients.
Perera GK; Child FJ; Heaton N; O'Grady J; Higgins EM
Br J Dermatol; 2006 May; 154(5):868-72. PubMed ID: 16634888
[TBL] [Abstract][Full Text] [Related]
15. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Herpes viruses and tumours in kidney transplant recipients. The role of immunosuppression.
Ponticelli C
Nephrol Dial Transplant; 2011 Jun; 26(6):1769-75. PubMed ID: 21482636
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
19. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
